JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist that does not inhibit related TRP channels such as TRPV2, TRPV4, or TRPA1. Listed in BJP with IC50= 65 nM. TRPV1 channels are activated by heat, capsaicin and the endocannabinoid anandamide. Interest in TRPV1 antagonists in the transmission and modulation of pain.
JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
We offer many products related to transient receptor potential channels for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.